Compare DEI & AXGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DEI | AXGN |
|---|---|---|
| Founded | 1971 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.2B |
| IPO Year | 2006 | 2013 |
| Metric | DEI | AXGN |
|---|---|---|
| Price | $12.38 | $39.49 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | $12.94 | ★ $42.33 |
| AVG Volume (30 Days) | ★ 2.2M | 1.4M |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | ★ 7.06% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,003,982,000.00 | $225,208,000.00 |
| Revenue This Year | $1.70 | $20.57 |
| Revenue Next Year | $2.35 | $16.68 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 1.77 | ★ 20.21 |
| 52 Week Low | $9.04 | $12.39 |
| 52 Week High | $16.94 | $46.95 |
| Indicator | DEI | AXGN |
|---|---|---|
| Relative Strength Index (RSI) | 53.87 | 43.09 |
| Support Level | $11.15 | $38.61 |
| Resistance Level | $12.70 | $39.99 |
| Average True Range (ATR) | 0.41 | 1.81 |
| MACD | -0.02 | -0.27 |
| Stochastic Oscillator | 52.24 | 18.62 |
Douglas Emmett Inc is an integrated, self-administered, and self-managed REIT. The group focuses on owning, acquiring, developing, and managing a substantial market share of office properties and multifamily communities in neighborhoods with supply constraints, high-end executive housing, and key lifestyle amenities. Its properties are located in the Beverly Hills, Brentwood, Burbank, Century City, Olympic Corridor, Santa Monica, Sherman Oaks/Encino, Warner Center/Woodland Hills and Westwood submarkets of Los Angeles County, California, and in Honolulu, Hawaii. It has two business segments: the office segment and multifamily segment, of which Office segment derives maximum revenue.
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.